T-cell helper type 1 response (Th1)

The T-cell helper type 1 (Th1) response is a core component of the adaptive immune system, primarily responsible for mediating host defense against intracellular pathogens such as viruses and certain bacteria (StatPearls, NBK541031). It is characterized by the differentiation of naive CD4+ T cells into Th1 effectors, a process regulated by the cytokines interleukin-12 (IL-12) and interleukin-18 (IL-18), and driven by the master transcription factor T-bet (NCBI, PMC3664276). Upon activation, Th1 cells produce signature cytokines, including interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), and interleukin-2 (IL-2), which activate macrophages and enhance the microbicidal activity of phagocytes. This response also plays a crucial role in anti-tumor immunity by promoting the expansion and activity of cytotoxic CD8+ T cells. However, a dysregulated or chronically active Th1 response is a significant factor in the pathophysiology of various organ-specific autoimmune and chronic inflammatory diseases, such as Crohn's disease, rheumatoid arthritis, and multiple sclerosis (PubMed, 11116246). Therapeutic strategies aimed at this response typically focus on neutralizing its effector cytokines or blocking the signaling pathways required for Th1 cell survival and function. For instance, monoclonal antibodies like adalimumab and ustekinumab target TNF-alpha and the IL-12/23 p40 subunit, respectively, to dampen Th1-mediated inflammation in clinical settings. Safety concerns associated with inhibiting this response include an increased susceptibility to opportunistic infections and the potential reactivation of latent tuberculosis (PubMed, 21245511).

Other names

Th1 cell-mediated immunityType 1 helper T cell responseType 1 immunityTh1-type cytokine response

The T-cell helper type 1 response is pharmacologically modulated through several mechanisms, including the neutralization of effector cytokines such as tumor necrosis factor-alpha (TNF-alpha) or the IL-12/23 p40 subunit, and the inhibition of calcineurin or dihydrofolate reductase to suppress T-cell activation and proliferation (StatPearls: Physiology, Helper T Cells; PubMed: 11116246).